Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAM-531 in mild to moderate Alzheimer's disease
NCT00481520Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vabicaserin in Alzheimer's disease (AD), sponsored by Pfizer. Primary endpoint: Safety and Tolerability at 28 days. Started Jun 2007; status: completed.
02
Drugs
vabicaserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00481520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00481520.